Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Prospective, Multicenter, Randomized, Double-blind, Sham-controlled Study of the Efficacy and Safety of STX-015 in the Treatment of Pain Associated With Lumbosacral Radiculopathy

NCT05614648 is registered in ClinicalTrials.gov with Sollis Therapeutics, Inc. as lead sponsor.

NCT NCT05614648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05614648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Prospective, Multicenter, Randomized, Double-blind, Sham-controlled Study of the Efficacy and Safety of STX-015 in the Treatment of Pain Associated With Lumbosacral Radiculopathy
Lead sponsor
Sollis Therapeutics, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 19, 2023
Completion date
March 30, 2024
Enrollment
17 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

lumbosacral radiculopathy